In progress

Today, the therapeutic management of patients with melanoma is a major challenge. Indeed, the latter is growing faster than all other cancers, especially in the young population. For the low impact of this therapies to toxicology, under add the toxicology. Of these, vaccines used dendritic cells (DCs) are generated ex-vivo from autologous CDs. They must be made to measure for each patient. This procedure is laborious and expensive, preventing the generalization of this immunotherapy. The in-vivo release of immunostimulatory molecules. In this context, we propose a therapeutic approach to the local delivery of a plasmid encoding interleukin-12, by ultrasound guided sonoporation (US). To achieve this goal, a new US probe will be developed and presented. The effectiveness of this therapy will be tested on a model of melanoma by imaging and by the analysis of the immune response. The purpose of the project is to make available to oncologists, this new therapeutic arsenal.

Project benefits

Emplois crées : 5

Action de communication : 20

Produit / Prototype : 5

People involved in the project

Member partner

No member partner



Information of the project

Start of the project on22 / 07 / 2024

Strategic business lines

Électronique : matériaux, composants et sous-systèmes

Referent of the project

Chargé de projets innovants

07 86 53 38 74

Centre-Val de Loire